Earlier this year, Pfizer, which is in the lead with an antibody trageting nerve growth factor one (NGF-1), announced that the Food and Drug Administration had told it to put clinical trials of its drug on hold.
But for the clinical translation of this technique, one would want to know whether the observations made with animal cells would also hold for human cells.